Aligning industry incentives with AMR control goals: Exploring the feasibility of an antibiotic susceptibility bonus for drugs to treat Gram-negative infection (ASB)

High prices create incentives for industry to develop new antibiotics, but also incentivize firms to promote their products to maximize sales volume. Similarly, the Market Entry Rewards proposed by the O’Neill Commission and others will, if introduced, help to get new drugs to market but do not directly address the problem of antibiotic overuse leading to emergence and spread of antimicrobial resistance (AMR) (O’Neill 2016).

Ongoing project

The multidisciplinary study proposed here explores the feasibility of a finance-based intervention intended to directly re-align pharmaceutical industry interests with the minimization of AMR and with the overall prolongation of antibiotic efficacy through time. The proposed intervention allows pharmaceutical companies to qualify for staged bonuses if pathogen susceptibility to their antibiotic remains above a given threshold, despite a certain minimum volume of usage. This Antibiotic Susceptibility Bonus may help maximize efforts towards good prescribing practice and towards minimizing the risk of acquisition, development and transmission of antibiotic-resistant Gram-negative bacteria. The lure of a bonus greater than expected revenues from unit sales could help align efforts behind antibiotic stewardship and infection prevention efforts in hospitals, communities, agriculture, and the environment, bolstering public and private AMR initiatives across One Health sectors.

This project will evaluate the feasibility and potential impact of the Antibiotic Susceptibility Bonus. It will address the difficulties involved in: i) developing a general measure of susceptibility; ii) calculating optimal bonuses based on realistic market considerations; iii) assessing product utility and accessibility. This will be done through 2-3 case studies of actual late stage (Phase III) candidate antibiotics and an existing product with particular antimicrobial features – each targeting multi-resistant Gram-negative bacteria.

 

Project partners

  • Aidan Hollis, University of Calgary, Canada (Coordinator)
  • Stephan Harbarth, University of Geneva, Switzerland
  • Olof Lindahl, Uppsala University, Sweden